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CAI, lowmutation pressure and very less adaption of tRNA pool of
equine cells. Hence, the study increased our understanding of
factors involved in viral adaptation, evolution, and ﬁtness towards
their hosts.
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Since 1963, Equine inﬂuenza virus (EIV) H3N8 subtype has been
responsible for numerous outbreaks of respiratory disease in
horses worldwide. The aim of this work was to study the mo-
lecular characteristics of H3N8 EIV detected in Argentina, esti-
mate their diversiﬁcation and infer the potential source of
infections. Nucleotide and deduced amino acid (aa) sequences for
the complete HA gene of the EIV detected in Argentina between
1985 and 2012 were analyzed along with sequences obtained
from the Inﬂuenza Research database. Maximum Likelihood (ML)
and Bayesian phylogenetic trees were built up. Bayesian coales-
cent analyses were carried out to estimate the time of the most
recent common ancestors (tMRCA) and the dynamic population
growth. The phylogenetic trees demonstrate that H3N8 EIV
detected in Argentina grouped in 4 well-supported monophyletic
clades: Group VIII (G.VIII), South American clade 1 (SA1) and 2
(SA2), and Florida clade 1 (FC1). The viruses circulating in
Argentina in 1985 (n¼2), together with a Chilean strain, formed
G.VIII (tMRCA~1984). The EIVs detected during the period 1993-
1996 (n¼5) grouped in the SA1 (tMRCA~1992), composed only by
Argentinian strains, and their most probable origin was a Ken-
tucky 1992 strain. The strains circulating in the period 1997-2005
(n¼8) grouped in the SA2 (tMRCA~1997), formed a monophyletic
group together with a 2006 Chilean strain, and were closely
related to California 1997 and Kentucky 1994 strains, feasible
ancestors of this group. The viruses detected in 2012 (n¼6)
grouped within the FC1 (tMRCA~2011) and formed a cluster with
the viruses detected in Florida in 2011. The demographic recon-
struction showed a remarkable increase in viral diversity in 2006,
a slight decrease between 2007 and 2009, and an abrupt decrease
since 2009. Compared with A/eq/Fontainebleau/79 (pre-diver-
gent prototype strain), Argentinean strains belonging to G.VIII
have 9 aa substitutions: T46I, A93T, R140K, T182S, G222W, V223I,
I267V, I187B and L199S, these last two situated at the antigenic
site B. In comparison with A/eq/Newmarket/1/93 (American
lineage reference strain), the SA 1 Argentinean viruses carried 4
aa substitutions: N132K, Q189N, Q190E and E193K, the last 3 at
the antigenic site B, and the SA2 strains showed only one aa
substitution at the antigenic site D (I214V). The possible ancestors
for SA1 and SA2 also possess the same aa substitutions at the
antigenic sites B and D, respectively. EIV Argentinean strains
detected in 2012 belonging to FC1 contained 5 aa substitutions in
comparison with A/eq/Ohio/01/03 (FC1 reference strain): G7D,
R62K, D104N, A138S and V223I. In addition, two different sub-
populations can be recognized among them, one with a substi-
tution in K-14A and the other one in K-14T and M70V, this last
(M70V) being present only in Argentinean strains. Except for K-
14A and M70V, the strain considered to be the origin of the group
(A/eq/Florida/146609/11) has the same aa substitutions. The ob-
tained results allow us to hypothesize that the outbreaks of
equine inﬂuenza in Argentina were due to 4 introductions of vi-
rus, presumably from North America. The rapid increase in therelative genetic diversity in 2006 could be due to the co-circula-
tion of different lineages, while the abrupt decline observed after
2009 could be related to a subsequent reduction in transmission
of EIV H3N8 connected to the incorporation of Florida Clade 2
strains in vaccines.
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In 1979, inﬂuenza caused a major epidemic amongst horses
across Europe including Newmarket, UK. Subsequently, vaccines
were produced using multiple outbreak strains including A/
equine/Newmarket/79 and A/equine/Fontainebleau/1/79 (both
subtype H3N8) which prevented further UK outbreaks until 1989
when a new antigenic drift variant emerged. The A/equine/Sus-
sex/89 (H3N8) strain came from one of the affected regions in the
UK where both unvaccinated and, notably, vaccinated horses
were affected. The accumulation of mutations within important
antigenic epitopes of the virus surface glycoprotein haemag-
glutinin (HA) can lead to a decrease in the efﬁciency of antibody
recognition. To study this phenomenon in relation to the
outbreak, three mutations, previously shown to have a pro-
nounced effect on recognition by ferret sera, have been incorpo-
rated into equine inﬂuenza pseudotyped lentiviruses (PVs). PVs
provide a ﬂexible platform for virological mutagenesis studies
and antibody screening assays. The PVs were generated via co-
transfection of HEK293T/17 cells with four plasmids expressing
the equine inﬂuenza HA surface glycoproteins, HIV gag-pol, ﬁreﬂy
luciferase reporter gene and TMPRSS2 endoprotease (to cleave
the HA which is necessary for viral infectivity). The resulting vi-
ruses were harvested and pseudotype virus antibody neutraliza-
tion assays (PVNAs) against Newmarket/79-speciﬁc sera (to
mimic the pre- and post-outbreak situation) were performed.
Neutralizing antibodies provide protection and the PVNA is a
sensitive technique to measure such protective antibody re-
sponses compared to other traditional assays (HI and SRH) that
measure antibody inhibited surface glycoprotein binding. The
PVNA highlighted speciﬁc single amino acid mutations in the
putative major epitope sites that altered the ability of the sera to
neutralize the PVs, indicating their importance in vaccine pro-
tection.
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Vaccination with inactivated vaccines is the primary means of
control of equine inﬂuenza which is caused by the infection with
equine inﬂuenza viruses of the H3N8 subtype. Many outbreaks
have been reported among vaccinated horses primarily due to the
antigenic mismatch between the vaccine strains and the ﬁeld
strains. We previously reported that the horse antiserum raised to
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Argentine sublineage), poorly cross-neutralizes some Florida
sublineage Clade (Fc) 2 strains which have one amino acid sub-
stitution at position 144 in antigenic site A of the hemagglutinin,
e.g. A/equine/Carlow/2011 (CL11). Because of that, Japanese vac-
cine manufacturers are updating their vaccines by replacing LP93
with a Fc2 strain, i.e. A/equine/Yokohama/aq13/2011 (Y10, Fc2).
We compared the efﬁcacy of the updated vaccine with that of the
vaccine containing LP93 in horses experimentally challenged
with CL11. Ten naïve horses were randomly separated into 2
groups, Y10 and LP93 groups. The horses in each group were
vaccinated twice one month apart by intramuscular injection of
the monovalent vaccine containing inactivated Y10 or LP93 strain.
Two horses in each groupwere experimentally infectedwith 109.4
50% egg infectious dose/horse of CL11, twoweeks after the second
vaccination. The remaining three horses in each group were
experimentally infected four weeks after second vaccination. The
rectal temperatures were recorded, and nasopharyngeal swabs
were collected daily for 14 days after the challenge. The geometric
mean (GM) of the virus neutralization (VN) titer against CL11 of
the Y10 and LP93 groups on the day of challenge, i.e. Day 0, was
48.5 and 10.6, respectively. Contrarily, the GM haemagglutination
inhibition (HI) titers against CL11 of the Y10 and LP93 groups on
Day 0 were similar (i.e. 27.9 or 24.3, respectively). The mean rectal
temperatures of the LP93 group were signiﬁcantly higher than
those of the Y10 group on Days 2 to 7, except for Day 4 after
challenge. The mean duration (3.0 days) of pyrexia (38.5C) of
the LP93 group was signiﬁcantly longer than that of Y10 group
(0.4 days). The virus was isolated from the swabs collected from
all the horses, except for two horses in the Y10 group. No signif-
icant difference in the duration of virus shedding was observed
between the groups. This study demonstrated the superior efﬁ-
cacy of the Y10 vaccine in terms of mitigation of pyrexia
compared to that of the LP93 vaccine. The GM HI titres against
CL11 were similar for the two groups on Day 0 and the difference
in vaccine efﬁcacy was probably due to the approx. 4.6-fold dif-
ference in GM VN titres between the groups. Thus this study
suggests that in horses, VN tests are more likely than HI tests to
identify antigenic differences in inﬂuenza viruses which could
affect vaccine efﬁcacy.
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Every year, several Equine Inﬂuenza (EI) epizooties are reported
worldwide, which may have important welfare and/or economic
consequences. EI vaccination is one of the most efﬁcient methods
of prevention. However, not all horses develop protective im-
munity after EI immunisation, increasing the risk of infection,
virus shedding and the spread of the disease. Objectives: This
study aimed to better understand the poor response to primary EI
vaccination. Study design: The EI antibody response was
measured in 117 thoroughbred foals set in 3 different stud farms
(SF#1 to SF#3) during primary EI immunisation with a commer-
cial recombinant canarypox-based EI vaccine, following themanufacturer recommendations. The age at ﬁrst vaccination was
159.3±27.6 days (17 to 37weeks). Serawere tested by single radial
haemolysis (SRH) against the A/equine/Jouars/4/2006 EIV strain
(H3N8; Florida Clade 2) at the time of the ﬁrst vaccination (V1), 2
weeks and 3 months after the second immunisation (V2), 2 days
and 3 months after the third immunisation (V3). Results: The
short (V2+2 weeks) and mid-term (V2+3 months and V3+3
months) SRH antibody levels were statistically different between
the stud farms (p-value¼0.031, 0.027 and 0.0003, respectively). At
both time points, SRH antibody titres were positively correlated to
the age of foals at V1 (p-value¼0.003 and 0.0038, respectively).
Presence of maternal derived antibody (MDA) at V1 had no
impact on short-term antibody titres (V2+2 weeks; p-value¼0.27)
but was negatively correlated with titres after V3 (p-val-
ue¼0.0056). Given that SF#1 antibody response was below clin-
ical protective levels (i.e. 85 mm2) at all time points studied, the
annual boost immunization (V4) was brought forward by 5.4±1
months to restore protective antibody levels. The average age at
ﬁrst immunisationwas delayed by 48.7 days the following year in
SF#1, which signiﬁcantly increased SRH antibody titres (p-val-
ue¼9.9e-07). Conclusion: Independently of the presence of MDA,
the age of foals at ﬁrst immunisationwith the canarypox-based IE
vaccine plays an important role in the establishment of adequate
antibody levels. This study also highlights the beneﬁt provided by
serological surveillance in order to evaluate the protection level of
a speciﬁc population, to identify poor vaccine responder and to
implement corrective management/vaccination measures.
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Current equine inﬂuenza vaccines elicit a strong humoral immune
response against surface glycoproteins, in particular haemag-
glutinin (HA). However, the virus undergoes continuous evolution
by mutation of sequences encoding amino acids, mostly those
present in the exposed head domain of HA, which results in poor
induction of cross-reactive antibodies against non-matching
strains. In contrast, it has been reported that epitopes in the stem
region of HA are highly conserved and can be used to stimulate a
